Sonoma Pharmaceuticals (SNOA) Non-Current Assets (2011 - 2026)

Sonoma Pharmaceuticals' Non-Current Assets history runs 16 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 77.99% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 11.49% increase from a year earlier, with the FY2026 full-year figure at $1.9 million, up 77.99% from the prior year.
• Non-Current Assets grew to $1.9 million in Q1 2026 per SNOA's latest filing, from $1.5 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $2.7 million in Q4 2022 and bottomed at $1.0 million in Q1 2025.
• The 5-year median for Non-Current Assets is $2.1 million (2023), against an average of $1.9 million.
• Across the five-year window, Non-Current Assets plunged 52.33% in 2025 and surged 77.99% in 2026, its largest moves.
• Year by year, Non-Current Assets stood at $2.7 million in 2022, then dropped by 21.51% to $2.1 million in 2023, then plunged by 39.13% to $1.3 million in 2024, then grew by 14.75% to $1.5 million in 2025, then gained by 25.85% to $1.9 million in 2026.
• Per Business Quant, the three latest SNOA Non-Current Assets figures stand at $1.9 million (Q1 2026), $1.5 million (Q4 2025), and $1.4 million (Q3 2025).